DAILY MORNING NOTE | 24 March 2026

Singapore stocks ended lower on Monday (Mar 23), mirroring regional peers. The local benchmark lost 2.2 per cent or 107.57 points to finish at 4,841.30. Meanwhile, the iEdge Singapore Next 50 Index gained 0.1 per cent or 1.2 points to 1,465.98. Across the broader market, losers beat gainers 554 to 144, after 2.1 billion securities worth S$2.8 billion changed hands.

In Monday’s regular session, the S&P 500 climbed 1.15%, while the tech-heavy Nasdaq rose 1.38%. The 30-stock Dow popped 631 points, or 1.38%. All three major averages posted their best session since early February. The gains came after President Donald Trump said in a Truth Social post that the U.S. and Iran have held very good and productive conversations regarding a complete and total resolution of our hostilities in the Middle East.

Singapore Technical Highlights

Factsheets


TOP 5 GAINERS & LOSERS

Factsheets


Events Of The Week

Factsheets


SG

A recent preferential offering for Lendlease Global Commercial Reit, to raise S$196.6 million to pay for its PLQ Mall stake buy, was only 62.2 per cent subscribed in what is a rare undersubscription. The real estate investment trust (Reit) is using the proceeds from the offering to take control of its remaining 30 per cent stake in PLQ Mall, giving it full ownership and operational control of the asset. The remaining funds are earmarked to cover related transaction costs and pare down existing debt.

Mapletree Logistics Trust has entered into an agreement to acquire a Grade A warehouse in Bhiwandi, Mumbai, for about 3.89 billion rupees (S$53.6 million). The transaction marks the trust’s first expansion into the Mumbai logistics market.

Singtel on Monday (Mar 23) was once again hit with user reports of disruption after three consecutive days of issues last week. The telco updated its post at 5.23 pm, saying that the disruption was due to an international traffic optimisation issue, and that this had been resolved within 15 minutes.


US

Berkshire Hathaway Inc will invest ¥287.4 billion (US$1.8 billion or $2.3 billion) in insurer Tokio Marine Holdings Inc, marking a significant increase in the US conglomerate’s exposure to the Japanese market. Tokio Marine will sell treasury shares to Berkshire Hathaway as part of its strategic partnership.

Toyota announced it would spend $1 billion total at two U.S. plants as part of a plan to invest up to $10 billion domestically over the next five years. The new investments include $800 million at a plant in Georgetown, Kentucky, to increase production capacity of its Camry sedan and RAV4 crossover. Automakers have been trying to navigate production plans amid tariffs and other regulatory changes.

Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the results, but cited strong efficacy for its decision to move forward. Partner Valneva has said the Lyme disease shot could reach annual peak sales of more than $1 billion.

Oil prices dropped about 11 per cent on Monday after US President Donald Trump said he would postpone any military strikes against Iranian power plants for five days and cited constructive talks to resolve hostilities in the Middle East, hours before a deadline that threatened to escalate the four-week-old war.

Apple said on Monday (Mar 23) that it would host its annual Worldwide Developers Conference (WWDC) online from Jun 8 to 12, showcasing updates across its platform, including artificial intelligence (AI) advancements and new software and developer tools.

Apple is preparing to introduce advertising in its Maps app, part of a broader push to generate more money from services. The system will operate similarly to advertising in Google Maps, allowing retailers and brands to bid for ad slots against search queries.

Estee Lauder said that it’s in talks to buy Puig in a deal that would create a cosmetics giant with about US$20 billion in annual sales. The companies declined to offer details on the terms. Puig, based in Spain, has a market value of about nine billion euros (S$13 billion).

Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. The deal includes about $1.68 billion in upfront cash, payable at closing, and up to $500 million in contingent milestone payments. Gilead said the deal would bolster its growing inflammation portfolio, adding gamgertamig.

Source: SGX Masnet, Bloomberg, Channel NewsAsia, Reuters, CNBC, WSJ, The Business Times, The Edge Singapore, PSR


RESEARCH REPORTS


Market Journal articles powered by PhillipGPT

17LIVE Group Limited Maintains BUY Rating Despite Revenue Decline

Frencken Group Positioned for Semiconductor Recovery

Ever Glory United Holdings Accelerates Growth Through Strategic Guthrie Acquisition


PSR Stocks Coverage

Factsheets


For more information, please visit:

https://www.stocksbnb.com/singapore-stocks-coverage/


Upcoming Webinars

Corporate Insights by LHN Ltd

Date & Time: 25 March 26 | 12PM-1PM

Register: poems-20260325-140477


Corporate Insights by Lum Chang Creations Limited

Date & Time: 27 March 26 | 12PM-1PM

Register: poems-20260327-141688


Corporate Insights by Thakral Corporation Ltd

Date & Time: 31 March 26 | 12PM-1PM

Register: poems-20260331-141690


Corporate Insights by Thakral Corporation Ltd

Date & Time: 31 March 26 | 6.30PM-7.30PM

Register: poems-20260331-141692


Corporate Insights by Beng Kuang Marine

Date & Time: 2 April 26 | 12PM-1PM

Register: poems-20260402-142364


Strategy & Stock Picks (Investment Symposium 2026) – SG Market [NEW]

Date & Time: 11 April 26 | 2.30PM-6PM

Register: poems-20260411-142749


POEMS Podcast:

Research Videos

https://www.youtube.com/embed/v72GfRG-rG8?list=PLv41YzcbRaXG98t4efd7aXkAfH33gq-2u
Date: 16 March 2026

Click here for more on Market Outlook.
Sign up for our webinars here, and be among the first to receive economy and market updates.

PHILLIP RESEARCH IN 3 MINS

Follow our Socials

Facebook Social Icon Instagram Icon Twitter Social Icon Youtube Social Icon Linkedin Social Icon TikTok Social Icon Spotify Social Icon

Join our Singapore Equity Research Community on POEMS Mobile 3 App for the latest research reports, market updates, insights and more

Click to join!

Disclaimer

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.

Confidentiality Note

This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com